Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Drug Profile

Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Alternative Names: Anti-CEACAM6 CAR-T cell therapy - Helix BioPharma; Anti-VEGFR2 CAR-T cell therapy - Helix BioPharma; Bispecific CAR-T cell therapy - Helix BioPharma; Chimeric Antigen Receptor-based cell therapies - Helix BioPharma; Tumour defence attackers - Helix BioPharma

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helix BioPharma
  • Class CAR-T cell therapies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Carcinoembryonic antigen modulators; Immunomodulators; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 04 Jan 2018 Helix BioPharma and ProMab Biotechnologies signed a binding letter of intent to co-develop CAR-T cell therapy for Haematological malignancies and Solid tumours
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 17 Mar 2017 Preclinical trials in Haematological malignancies in Canada (Parenteral) (Helix BioPharma pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top